1 result

    A multicenter, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of omecamtiv mecarbil on mortality and morbidity in subjects with chronic heart failure with reduced ejection fraction.

    Type: Drug trial

    Principal Investigator: Mark J. Zucker, MD, JD

    Trial is not open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center